vs
Apellis Pharmaceuticals, Inc.（APLS）与Stitch Fix, Inc.（SFIX）财务数据对比。点击上方公司名可切换其他公司
Stitch Fix, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$342.1M vs $199.9M），Stitch Fix, Inc.净利率更高（-1.9% vs -29.5%，领先27.6%），Stitch Fix, Inc.同比增速更快（7.3% vs -5.9%），Stitch Fix, Inc.自由现金流更多（$5.6M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Stitch Fix是美国的在线个人造型服务平台，依托推荐算法与数据科学技术，根据顾客的身形尺寸、预算和风格偏好推送个性化服饰单品。该公司创立于2011年，2017年完成首次公开募股，目前总部位于旧金山。
APLS vs SFIX — 直观对比
营收规模更大
SFIX
是对方的1.7倍
$199.9M
营收增速更快
SFIX
高出13.2%
-5.9%
净利率更高
SFIX
高出27.6%
-29.5%
自由现金流更多
SFIX
多$19.9M
$-14.3M
两年增速更快
APLS
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $342.1M |
| 净利润 | $-59.0M | $-6.4M |
| 毛利率 | — | 43.6% |
| 营业利润率 | -25.6% | -2.5% |
| 净利率 | -29.5% | -1.9% |
| 营收同比 | -5.9% | 7.3% |
| 净利润同比 | -62.2% | -1.7% |
| 每股收益（稀释后） | $-0.40 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSFIX
| Q4 25 | $199.9M | $342.1M | ||
| Q3 25 | $458.6M | $311.2M | ||
| Q2 25 | $178.5M | $325.0M | ||
| Q1 25 | $166.8M | $312.1M | ||
| Q4 24 | $212.5M | $318.8M | ||
| Q3 24 | $196.8M | $319.6M | ||
| Q2 24 | $199.7M | $322.7M | ||
| Q1 24 | $172.3M | $330.4M |
净利润APLSSFIX
| Q4 25 | $-59.0M | $-6.4M | ||
| Q3 25 | $215.7M | $-8.6M | ||
| Q2 25 | $-42.2M | $-7.4M | ||
| Q1 25 | $-92.2M | $-6.5M | ||
| Q4 24 | $-36.4M | $-6.3M | ||
| Q3 24 | $-57.4M | $-36.5M | ||
| Q2 24 | $-37.7M | $-21.3M | ||
| Q1 24 | $-66.4M | $-35.5M |
毛利率APLSSFIX
| Q4 25 | — | 43.6% | ||
| Q3 25 | — | 43.6% | ||
| Q2 25 | — | 44.2% | ||
| Q1 25 | — | 44.5% | ||
| Q4 24 | — | 45.4% | ||
| Q3 24 | — | 44.6% | ||
| Q2 24 | — | 45.5% | ||
| Q1 24 | — | 43.4% |
营业利润率APLSSFIX
| Q4 25 | -25.6% | -2.5% | ||
| Q3 25 | 48.7% | -3.6% | ||
| Q2 25 | -18.6% | -3.0% | ||
| Q1 25 | -50.0% | -2.9% | ||
| Q4 24 | -12.3% | -2.8% | ||
| Q3 24 | -24.0% | -13.1% | ||
| Q2 24 | -14.7% | -7.7% | ||
| Q1 24 | -36.0% | -11.5% |
净利率APLSSFIX
| Q4 25 | -29.5% | -1.9% | ||
| Q3 25 | 47.0% | -2.8% | ||
| Q2 25 | -23.6% | -2.3% | ||
| Q1 25 | -55.3% | -2.1% | ||
| Q4 24 | -17.1% | -2.0% | ||
| Q3 24 | -29.2% | -11.4% | ||
| Q2 24 | -18.9% | -6.6% | ||
| Q1 24 | -38.5% | -10.8% |
每股收益（稀释后）APLSSFIX
| Q4 25 | $-0.40 | $-0.05 | ||
| Q3 25 | $1.67 | $-0.06 | ||
| Q2 25 | $-0.33 | $-0.06 | ||
| Q1 25 | $-0.74 | $-0.05 | ||
| Q4 24 | $-0.30 | $-0.05 | ||
| Q3 24 | $-0.46 | $-0.29 | ||
| Q2 24 | $-0.30 | $-0.18 | ||
| Q1 24 | $-0.54 | $-0.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $244.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $204.1M |
| 总资产 | $1.1B | $530.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSFIX
| Q4 25 | $466.2M | $244.2M | ||
| Q3 25 | $479.2M | $234.9M | ||
| Q2 25 | $370.0M | $234.2M | ||
| Q1 25 | $358.4M | $219.1M | ||
| Q4 24 | $411.3M | $253.3M | ||
| Q3 24 | $396.9M | $247.0M | ||
| Q2 24 | $360.1M | $244.5M | ||
| Q1 24 | $325.9M | $229.8M |
总债务APLSSFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSSFIX
| Q4 25 | $370.1M | $204.1M | ||
| Q3 25 | $401.2M | $203.0M | ||
| Q2 25 | $156.3M | $200.4M | ||
| Q1 25 | $164.2M | $197.8M | ||
| Q4 24 | $228.5M | $190.5M | ||
| Q3 24 | $237.1M | $187.0M | ||
| Q2 24 | $264.3M | $208.9M | ||
| Q1 24 | $266.7M | $213.3M |
总资产APLSSFIX
| Q4 25 | $1.1B | $530.7M | ||
| Q3 25 | $1.1B | $480.6M | ||
| Q2 25 | $821.4M | $484.7M | ||
| Q1 25 | $807.3M | $472.6M | ||
| Q4 24 | $885.1M | $507.1M | ||
| Q3 24 | $901.9M | $486.9M | ||
| Q2 24 | $904.5M | $537.0M | ||
| Q1 24 | $831.9M | $538.3M |
负债/权益比APLSSFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $10.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $5.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 1.6% |
| 资本支出强度资本支出/营收 | 0.1% | 1.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $4.9M |
8季度趋势，按日历期对齐
经营现金流APLSSFIX
| Q4 25 | $-14.2M | $10.9M | ||
| Q3 25 | $108.5M | $7.0M | ||
| Q2 25 | $4.4M | $20.5M | ||
| Q1 25 | $-53.4M | $-16.2M | ||
| Q4 24 | $19.4M | $14.3M | ||
| Q3 24 | $34.1M | $8.2M | ||
| Q2 24 | $-8.3M | $21.7M | ||
| Q1 24 | $-133.0M | $-22.3M |
自由现金流APLSSFIX
| Q4 25 | $-14.3M | $5.6M | ||
| Q3 25 | $108.3M | $2.8M | ||
| Q2 25 | $4.4M | $16.0M | ||
| Q1 25 | $-53.4M | $-19.4M | ||
| Q4 24 | $19.3M | $9.9M | ||
| Q3 24 | — | $4.5M | ||
| Q2 24 | $-8.4M | $18.9M | ||
| Q1 24 | $-133.3M | $-26.1M |
自由现金流率APLSSFIX
| Q4 25 | -7.1% | 1.6% | ||
| Q3 25 | 23.6% | 0.9% | ||
| Q2 25 | 2.5% | 4.9% | ||
| Q1 25 | -32.0% | -6.2% | ||
| Q4 24 | 9.1% | 3.1% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | -4.2% | 5.9% | ||
| Q1 24 | -77.3% | -7.9% |
资本支出强度APLSSFIX
| Q4 25 | 0.1% | 1.6% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | 0.0% | 0.9% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率APLSSFIX
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SFIX
暂无分部数据
